Research Square
Alzheimer disease risk estimates lose clinical calibration across study phases despite useful patient ranking
Preprint: cohort study of 1,002 peopleBiomarkers
24 months
Abstract
Risk prediction in Alzheimer disease can guide follow-up, biomarker testing, trial referral, and prognostic counseling. Clinical use of an estimated 24-month probability requires both useful ranking and a probability scale that retains its meaning when the population changes.
The paper
University of Illinois Chicago
Research Square, 4 Sep 2026, CC BY, Preprint, not peer-reviewed
